Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel ...

Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...

FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...

Novartis announced topline results from a pre-specified interim analysis of the phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Monday positive topline results from a pre-specified interim analysis of the Phase III PSMAddition trial for Pluvicto plus hormone therapy ...

In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic ...

Novartis Pharma AG. Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for ...